Fernando Villalta to Chagas Disease
This is a "connection" page, showing publications Fernando Villalta has written about Chagas Disease.
Connection Strength
3.387
-
Villalta F, Rachakonda G. Advances in preclinical approaches to Chagas disease drug discovery. Expert Opin Drug Discov. 2019 11; 14(11):1161-1174.
Score: 0.657
-
Lepesheva GI, Hargrove TY, Rachakonda G, Wawrzak Z, Pomel S, Cojean S, Nde PN, Nes WD, Locuson CW, Calcutt MW, Waterman MR, Daniels JS, Loiseau PM, Villalta F. VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis. J Infect Dis. 2015 Nov 01; 212(9):1439-48.
Score: 0.487
-
Villalta F, Dobish MC, Nde PN, Kleshchenko YY, Hargrove TY, Johnson CA, Waterman MR, Johnston JN, Lepesheva GI. VNI cures acute and chronic experimental Chagas disease. J Infect Dis. 2013 Aug 01; 208(3):504-11.
Score: 0.418
-
Villalta F, Scharfstein J, Ashton AW, Tyler KM, Guan F, Mukherjee S, Lima MF, Alvarez S, Weiss LM, Huang H, Machado FS, Tanowitz HB. Perspectives on the Trypanosoma cruzi-host cell receptor interactions. Parasitol Res. 2009 Jun; 104(6):1251-60.
Score: 0.319
-
Simmons KJ, Nde PN, Kleshchenko YY, Lima MF, Villalta F. Stable RNA interference of host thrombospondin-1 blocks Trypanosoma cruzi infection. FEBS Lett. 2006 Apr 17; 580(9):2365-70.
Score: 0.261
-
Arun A, Rayford KJ, Cooley A, Rana T, Rachakonda G, Villalta F, Pratap S, Lima MF, Sheibani N, Nde PN. Thrombospondin-1 expression and modulation of Wnt and hippo signaling pathways during the early phase of Trypanosoma cruzi infection of heart endothelial cells. PLoS Negl Trop Dis. 2022 01; 16(1):e0010074.
Score: 0.194
-
Guedes-da-Silva FH, Batista DDGJ, Da Silva CF, Pav?o BP, Batista MM, Moreira OC, Souza LRQ, Britto C, Rachakonda G, Villalta F, Lepesheva GI, Soeiro MNC. Successful Aspects of the Coadministration of Sterol 14a-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi. ACS Infect Dis. 2019 03 08; 5(3):365-371.
Score: 0.158
-
Friggeri L, Hargrove TY, Rachakonda G, Blobaum AL, Fisher P, de Oliveira GM, da Silva CF, Soeiro MNC, Nes WD, Lindsley CW, Villalta F, Guengerich FP, Lepesheva GI. Sterol 14a-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae. J Med Chem. 2018 12 13; 61(23):10910-10921.
Score: 0.157
-
Suman S, Rachakonda G, Mandape SN, Sakhare SS, Villalta F, Pratap S, Lima MF, Nde PN. Phospho-proteomic analysis of primary human colon epithelial cells during the early Trypanosoma cruzi infection phase. PLoS Negl Trop Dis. 2018 09; 12(9):e0006792.
Score: 0.154
-
Farrow AL, Rachakonda G, Gu L, Krendelchtchikova V, Nde PN, Pratap S, Lima MF, Villalta F, Matthews QL. Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2014 Aug; 8(8):e3089.
Score: 0.116
-
Dobish MC, Villalta F, Waterman MR, Lepesheva GI, Johnston JN. Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease. Org Lett. 2012 Dec 21; 14(24):6322-5.
Score: 0.103
-
Johnson CA, Kleshchenko YY, Ikejiani AO, Udoko AN, Cardenas TC, Pratap S, Duquette MA, Lima MF, Lawler J, Villalta F, Nde PN. Thrombospondin-1 interacts with Trypanosoma cruzi surface calreticulin to enhance cellular infection. PLoS One. 2012; 7(7):e40614.
Score: 0.101
-
Villalta F, Madison MN, Kleshchenko YY, Nde PN, Lima MF. Molecular analysis of early host cell infection by Trypanosoma cruzi. Front Biosci. 2008 May 01; 13:3714-34.
Score: 0.075
-
Nde PN, Simmons KJ, Kleshchenko YY, Pratap S, Lima MF, Villalta F. Silencing of the laminin gamma-1 gene blocks Trypanosoma cruzi infection. Infect Immun. 2006 Mar; 74(3):1643-8.
Score: 0.065
-
Rayford KJ, Cooley A, Arun A, Rachakonda G, Kleschenko Y, Villalta F, Pratap S, Lima MF, Nde PN. Trypanosoma cruzi Modulates PIWI-Interacting RNA Expression in Primary Human Cardiac Myocytes during the Early Phase of Infection. Int J Mol Sci. 2020 Dec 11; 21(24).
Score: 0.045
-
Hoekstra WJ, Hargrove TY, Wawrzak Z, da Gama Jaen Batista D, da Silva CF, Nefertiti AS, Rachakonda G, Schotzinger RJ, Villalta F, Soeiro Mde N, Lepesheva GI. Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi. Antimicrob Agents Chemother. 2016 Feb; 60(2):1058-66.
Score: 0.032
-
Lepesheva GI, Villalta F, Waterman MR. Targeting Trypanosoma cruzi sterol 14a-demethylase (CYP51). Adv Parasitol. 2011; 75:65-87.
Score: 0.023
-
Lepesheva GI, Hargrove TY, Anderson S, Kleshchenko Y, Furtak V, Wawrzak Z, Villalta F, Waterman MR. Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi. J Biol Chem. 2010 Aug 13; 285(33):25582-90.
Score: 0.022